Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
In HIV-infected subjects with haemophilia, CD4 counts seem to fall more slowly in those on high-purity factor VIII (FVIII) than on intermediate-purity product. We evaluated whether risks for AIDS or death were associated with either product among 411 HIV-infected individuals. The relative hazard of AIDS was slightly elevated for both current (1.34) [corrected] and cumulative (1.01 per month) use of high-purity products (neither significant). The corresponding hazards for death were 1.49 and 1.03 (neither significant). Thus we found no evidence that high-purity FVIII concentrates retard the development of AIDS.
Goedert
J J
JJ
AIDS and Cancer Section, Viral Epidemiology Branch, National Cancer Institute, Rockville, Maryland.
Cohen
A R
AR
Kessler
C M
CM
Eichinger
S
S
Seremetis
S V
SV
Rabkin
C S
CS
Yellin
F J
FJ
Rosenberg
P S
PS
Aledort
L M
LM
D000163:Acquired Immunodeficiency Syndrome / Q000209:etiology* / Q000276:immunology / Q000401:mortality; D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D015331:Cohort Studies; D005169:Factor VIII / Q000592:standards* / Q000627:therapeutic use*; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007958:Leukocyte Count; D011237:Predictive Value of Tests; D012307:Risk Factors
D005169:Factor VIII